EXAS Jul 2024 67.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:56PM EDT
Loading interactive chart…
- Zacks
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
- Zacks
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
- Business Wire
Exact Sciences to Participate in June Investor Conferences
MADISON, Wis., May 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
© 2024 Yahoo. All rights reserved.